Short Term Rating on ACADIA Pharmaceuticals (ACAD)

ACADIA Pharmaceuticals (ACAD) has an average broker rating of 1.57, which is interpreted as a Buy, as rated by 7 equity analysts. Nonetheless, 5 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

ACADIA Pharmaceuticals (ACAD) stock is expected to deviate a maximum of $6.65 from the average target price of $46.44 for the short term period. 9 Street Experts have initiated coverage on the stock with the most promising target being $55 and the most muted being $35.

For the current week, the company shares have a recommendation consensus of Buy.


ACADIA Pharmaceuticals (NASDAQ:ACAD): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $34.37 and $34.29 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $35.06. The buying momentum continued till the end and the stock did not give up its gains. It closed at $34.68, notching a gain of 2.24% for the day. The total traded volume was 1,304,153 . The stock had closed at $33.92 on the previous day.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.